![肿瘤药物治疗方案及综合评价](https://wfqqreader-1252317822.image.myqcloud.com/cover/13/43604013/b_43604013.jpg)
上QQ阅读APP看本书,新人免费读10天
设备和账号都新为新人
第十章 胃癌
胃癌术后辅助化疗方案Ⅰ
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T194_287_1157_2077_1521_148539.jpg?sign=1738830016-oh67HbBdkk6bKHlzYN7FsnL9u4uiROit-0-6a37645e81cc259af3297493d746f737)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T194_297_1616_2007_2837_100296.jpg?sign=1738830016-KvFhRd7TbrjL8Ep9zWg386boelc5RdPV-0-1bdb6f24e06a81cb360713a6067a4d4c)
续表
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T195_238_343_1948_1238_146938.jpg?sign=1738830016-dYwD1pyOpSt5Kf9zbPzWqcQZxO0HGejx-0-ccf3c96e6d2cd504eea713b9bc8492bf)
点评
XELOX方案为胃癌D2术后标准辅助化疗方案,其证据CLASSIC研究(NCT00411229)为Ⅲ期多中心随机对照试验,旨在比较胃癌D2术后辅助化疗(卡培他滨+奥沙利铂)的有效性。适用人群为Ⅱ~ⅢB期接受D2切除术后,ECOG评分0~1分的胃癌患者。该研究是首个纳入中国人群的大型国际多中心Ⅲ期胃癌辅助化疗研究,奠定了胃癌D2术后辅助化疗的地位。
(张 涛 于丹丹)
参考文献
[1] NOH SH,PARK SR,YANG H-K,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial.Lancet Oncology,2014,15:1389-1396.
[2] BANG Y-J,KIM Y-W,YANG H-K,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label,randomised controlled trial.Lancet,2012,379:315-321.